Thunder Biotech
Thunder Biotech specializes in developing immunotherapies for cancer, focusing on its MOTO-CAR technology that genetically engineers macrophages to target and destroy tumor cells, particularly in solid tumors.
Company Overview
Thunder Biotech is a biotechnology company focused on revolutionary cancer treatments through the use of immunotherapy. Located at 395 West Cougar Blvd., Suite 103, Sorenson Legacy Tower, Provo, UT 84604, the company specializes in genetically engineering macrophages to enable cancer patients' cells to recognize and attack tumor cells. Their primary aim is to offer more effective and humane treatments for patients with solid tumors.
MOTO-CAR Immunotherapy
Thunder Biotech is developing MOTO-CAR immunotherapy, a sophisticated treatment modality designed to activate a patient's own immune system to combat cancer. MOTO-CAR technology involves the genetic engineering of a patient's immune cells into MOTO-CAR cells, specifically targeting biomarkers found on tumor cells. This innovative approach shows promise in disrupting traditional cancer treatment methods and improving patient outcomes.
Pipeline and Development Stages
Thunder Biotech's pipeline encompasses a range of programs at different stages of development, including early discovery, late discovery, preclinical, and phase I trials. The company's primary focus is on solid tumors, which account for 92 percent of all cancers. The preliminary data show that MOTO-CAR adjustments can seek and destroy tumor cells in animal models.
Focus on Solid Tumors
Thunder Biotech's MOTO-CAR platform is designed to attack a wide range of cancers, with a current concentration on solid tumors. Solid tumors constitute the majority of cancer cases, and the MOTO-CAR technology aims to provide a groundbreaking approach to treatment by leveraging the body's own immune system to target and eliminate these tumors.